Physiopathologic role of TGF-β in nephropathies of diverse etiologies. I. Physiopathologic role of TGF-β in nephropathies of diverse etiologies: TGF-βinhibitors as potential therapeutic agents;Receptores y funciones del TGF-beta, una citocina crucial en la cicatrización. I. El papel fisiopatológico del TGF-β en las nefropatías de diversas etiologías: Los inhibidores del TGF-β como agentes terapéuticos potenciales

Gaceta Medica de Mexico

Volumn 139, Issue 2, 2003, Pages 126-134

  García Sainz, J Adolfo ^b   Vilchis Landeros, M Magdalena ^a   Juárez, Patricia ^a   López Casillas, Fernando ^a,b  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; OLIGONUCLEOTIDE; TRANSFORMING GROWTH FACTOR BETA;

CONFERENCE PAPER; DRUG MECHANISM; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INHIBITION KINETICS; KIDNEY DISEASE; NONHUMAN; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

COMMUNICABLE DISEASES; DNA-BINDING PROTEINS; HUMANS; IMMUNE SYSTEM DISEASES; INFLAMMATION; KIDNEY DISEASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; SMAD4 PROTEIN; TRANS-ACTIVATORS; TRANSFORMING GROWTH FACTOR BETA; WOUND HEALING;

EID: 0038031570     PISSN: 00163813     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (68)

1. Escobedo-De la Peña J, Rico-Verdín B. Incidencia y letalidad de las complicaciones agudas y crónicas de la diabetes mellitus en México. Salud Pública de Méx 1996;38:236-242.
2. Garza R, Medina R, Basu S, Pugh JA. Predictors of the rate of renal function decline in non-insulin-dependent diabetes mellitus. Am J Nephrol 1997;17:59-67.
3. Sharma K, Ziyadeh FN. The emerging role of transforming growth factor-β in kidney diseases. Am J Physiol 1994;266: F829-F842.
4. Reeves WB, Andreoli TE. Transforming growth factor β contributes to progressive diabetic nephropathy. Proc Natl. Acad Sci USA 2000;97:7667-7669.
5. Massagué J. The transforming growth factor-β famiiy. Annu Rev Cell Biol 1990;6:597-641.
6. Roberts AB, Sporn MB. Physiological actions and clinical applications of transforming growth factor-β (TGF-β). Growth Factors 1993;8:1-9.
7. Massagué J, Blain SW, Lo RS. TGFβ signaling in growth control, cancer, and heritable disorders. Cell 2000;103:295-309.
8. Letterio JL, Roberts AB. Regulation of the immune response by TGF-β. Annu. Rev. Immunol. 1998;16:137-161.
9. Shuil MM, Ormsby I, Kier AB, et al. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory response. Nature 1992;359:693-699.
10. Kuíkarni AB, Karisson S. Transforming growth factor-beta 1 knockout mice. A mutation in one cytokine gene causes a dramatic inflammatory disease. Am J Pathol 1993;143:3-9.
11. Sanford LP, Ormsby I, Gittenberger-de Groot A, et al. TGFβ2 knockout mice have multiple developmental defects that are non overiapping with other TGFβ knockout phenotypes. Development 1997;124:2659-2670.
12. Kaartinen V, Voncken JW, Shuier C, et al. Abnormal lung development and cleft palate in mice lacking TGF-β3 indicates defects in epithelial-mesenchymal interaction. Nature Genet 1995;11:415-421.
13. Border WA, Ruoslahti E. Transforming growth factor-β in disease: the darkside of tissue repair. J Clin Invest 1992;90:1-7.
14. Wahl SM. Transforming growth factor beta (TGF-β) in inflammation: a cause and a cure. J Clin Immunol 1992;12:61-74.
15. Munger JS, Harpel JG, Gleizes P-E, Mazzieri R, Nunes I, Rifkin DB. Latent transforming growth factor-β: structural features and mechanisms of activation. Kidney Int 1997;51: 1376-1382.
16. Murphy-Ulirich JE, Poczatek M. Activation of latent TGF-β by thrombospondin-I: mechanisms and physiology. Cytokine Growth Factor Rev 2000;11:59-69.
17. Crawford SE, Stelimach V, Murphy-Ulirich JE, et al. Thrombospondin-1 is a major activator of TGF-β1 in vivo. Cell 1998; 93:1159-1170.
18. Ribeiro SMF, Poczatek M, Schultz-Cherry S, Villain M, Murphy-Ulirich JE. The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent Transforming Growth Factor-β. J Biol Chem 1999;274:13586-13593.
19. Munger JS, Huang X, Kawakatsu H, et al. The integrin avb6 binds and activates latent TGFβ1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999;96:319-328.
20. Ciark DA, Coker R. Transforming growth factor-beta (TGF-beta). Int J Biochem Cell Biol 1998;30:293-8.
21. Massagué J. TGF-β signal transduction. Annu Rev Biochem 1998 67:753-791.
22. Massagué J, Chen Y-G. Controlling TGF-β signalling. Genes Dev 2000;14:627.
23. Massagué J. How cells read TGF-β signals. Nat Rev Mol Cell Biol 2000;1:169-178.
24. Piek E, Heidin C-H, ten Dijke P. Specificity, diversity and regulation in TGF-β superfamily signaling. FASEB J 1999;13:2105-2124.
25. Wrana JL. Regulation of Smad activity. Cell 2000;100:189-192.
26. Hayashi H, Abdollah S, Qui Y, et al. The MAD-related protein Smad7 associates with the TG FP receptor and functions as an antagonist of TGFβ signaling. Cell 1997;89:1165-1173.
27. Nakao A, Afrakhte M, Moren A, et al. Identification of Smad7. a TGFβ-inducible antagonist of TGF-β signaling. Nature 1997;389:631-635.
28. Biobe GC, Schiemann WP, Lodish HF. Role of Transforming Growth Factor β in Human Disease. N Engl J Med 2000;342:1350-1358.
29. López-Casillas F. El TGF-β (Transforming Growth Factor tipo beta), piedra angular en la nefropatía diabética. Rev Invest Clin 2000;52:487-490.
30. Lang F, Kiingel K, Wagner CA, et al. Deranged transcriptional regulation of celivolume-sensitive kinase HSGK in diabetic nephropathy. Proc Natl Acad Sci USA 2000;97:8157-8162.
31. Border WA, Okuda S, Languino LR, Spom MB, Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor βI. Nature 1990;346:371-374.
32. Sharma K,Jin Y, Guo J, Ziyadeh FN. Neutralization of TGF-β by anti-TGF-β antibody attenuates kidney hypertrophy and enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996;45:522-530.
33. Ziyadeh FN, Hoffi-nan BB, Han DC, et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular messangial matrix expansion by treatment with monoclonal antitransforming growth factor-β antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000;97:8015-8020.
34. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA. Expression of transforming growth factor β is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 1993;90:1814-1818.
35. Sharma K, Ziyadeh FN, Alzahabi B, et al. Increased renal production of transforming growth factor-βI in patients with type II diabetes. Diabetes 1997;46:854-859.
36. Border WA, Noble NA, Yamamoto T, et al. Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature 1992;360:361-364.
37. Isaka Y, Brees DK, Ikegaya K, et al. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med 1996;2:418-23.
38. Koib M, Margetts PJ, Galt T, et al. Transient transgene expression of decorin in the lung reduces the fibrotic response to bleomycin. Am J Respir Crit Care Med 2001;163:770-7.
39. Takeuchi Y, Kodama Y, Matsumoto T. Bone matrix decorin binds transforming growth factor-beta and enhances its bioactivity. J Biol Chem 1994;269:32634-8.
40. Iozzo RV, Moscatello DK, McQuillan DJ, Eichstetter I. Decorin is a biological ligand for the epidermal growth factor receptor. J Biol Chem 1999;274:4489-4492.
41. Lin HY, Moustakas A, Knaus P, Weiis RG, Henis YI, Lodish HF. The soluble exoplasmic domain of the type II transforming growth factor (TGF)-β receptor. J Biol Chem 1995;270:2747-2754.
42. George J, Roulot D, Koteliansky VE, Bissell DM. In vivo inhibition of rat stellate cell activaron by soluble transforming growth factor beta type II receptor: a potencial new therapy for hepatic fibrosis. Proc Natl Acad Sci USA 1999;96:12719-12724.
43. Isaka Y, Akagi Y, Ando Y, et al. Gene therapy by transforming growth factor-beta receptor-IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 1999;55:465-475.
44. Bóttinger EP, Factor VM, Tsang MLS, et al. The recombinant proregion of transforming growth factor βI (Latency-associated peptide) inhibits active transforming growth factor β1 in transgenic mice. Proc Natl Acad Sci USA 1996;93:5877-5882.
45. Huang SS, Liu Q, Johnson FE, Konish Y, Huang JS. Transforming growth factor beta peptide antagonists and their conversion to partial agonists. J Biol Chem 1997;272:27155-27159.
46. Hugo CPM, Pichler RP, Schuize-Lohoff E, et al. Thrombospondin peptides are potent inhibitors of messangial and glomerular endothelial cell proliferation in vitro and in vivo. Vjdney Int 1999;55:2236-2249.
47. Akagi Y, Isaka Y, Aral M, et al. Inhibition of TGF-beta 1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 1996;50:148-55.
48. Armendariz-Borunda J, LeGros L, Jr., Campollo O, Panduro A, Rincon AR. Antisense S-oligodeoxynucleotides down-regulate TGFbeta-production by Kupffer cells from CC14-injured rat livers. Biochim Biophys Acta 1997;1353:241-252.
49. Isaka Y, Tsujie M, Ando Y, et al. Transforming growth factor-beta 1 antisense oligodeoxynucleotides block interstitial fibrosis in unilateral ureteral obstruction. Kidney fnt 2000;58:1885-92.
50. Han DC, Hoffman BB, Hong SW, Guo J, Ziyadeh FN. Therapy with antisense TGF-betaI oligodeoxynucleotides reduces kidneyweight and matrix mRNAs in diabetic mice. Am J Physiol Renal Physiol 2000;278:F628-34.
51. Nakao A, Fujii M, Matsumara R, et al. Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J Clin Invest 1999;104:5-11.
52. Laping NJ, Grygielko E, Mathur A, et al. Inhibition of TGF-beta 1-induced extracellular matrix wfth a novel selective inhibitor of the TGF-beta type I receptor kinase activity. J Am Soc Nephrol 2001;12:595A.
53. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037.
54. López-Casillas F, Wrana JL, Massagué J. Betaglycan presents ligand to the TGF-β signaling receptor. Cell 1993;73:1435-1444.
55. Headlines. Receptor of the third kind. Trends in Cell Biol 1993;3:334.
56. López-Casillas F, Cheifetz S, Doody J, Andrés JL, Lane WS, Massagué J. Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-β receptor system. Cell 1991;67:785-795.
57. Ponce-Castañeda MV, Esparza-López J, Vilchis-Landeros MM, Mendoza R. V, López-Casillas F. Murine betaglycan primary structure, expression and glycosaminoglycan attachment sites. Biochim Biophys Acta 1998;1384:189-196.
58. López-Casillas F, Payne HM, Andrés JL, Massagué J. Betaglycan can act as dual modulator of TGF-β access to signaling receptors: mapping of ligand binding and GAG attachment sites. J Cell Biol 1994;124:557-568.
59. Esparza-López J, Montiel JL, Vilchis-Landeros MM, Okadome T, Miyazono K, López-Casillas F. Ligand binding and functional properties of betaglycan, a coreceptor of transforming growth factor-β superfamily. Specialized binding regions for transforming growth factor-o and inhibin. A J Biol Chem 2001;276:14588-4596.
60. Andres J, DeFalcis D, Noda M, Massagué J. Binding of two growth factor families to separate domains of the proteoglycan betaglycan. J Biol Chem 1992;267:5927-5930.
61. Lewis KA, Gray PC, Blount AL, et al. Betaglycan binds inhibin and can mediate functional antagonism of activin signaling. Nature 2000;404:411-414.
62. Bernard DJ, Chapman SC, Woodruff TK. Inhibin binding protein (inhBPIp/20), betaglycan, and thecontinuing search for the inhibin receptor. Mol Endocrinol 2002;16:207-212.
63. Andres JL, Stanley K, Cheifetz S, Massagué, J. Membrane-anchored and soluble forms of betaglycan, a polymorphic proteoglycan that binds transforming growth factor-β. J Cell Biol 1989;109:3137-3145.
64. Arribas J, López-Casillas F, Massagué J. Role of juxtamembrane domains of the transforming growth factor-α precursor and the β-amyloid protein in the regulated ectodomain shedding. J Biol Chem 1997;272:17160-17165.
65. Vilchis-Landeros MM, Montiel JL, Mendoza V, Mendoza-Hemández G, López-Casillas F. Recombinant soluble beta-glycan is a potent and isoform-selective transforming growth factor-β neutralizing agent. Biochem J 2001;355:215-222.
66. Attisano L, Wrana JL, López-Casillas F, Massagué J. TGF-β receptors and actions. Biochim Biophys Acta 1994;1222:71-80.
67. López-Casillas F, Vilchis-Landeros MM, Mendoza M, Aguilar-Leon D, Hemández-Pando R. Anti-thymocyte serum-induced glomerulonephritis is prevented by recombinant soluble betaglycan, an inhibitor of Transforming Growth Factor-b. J Am Soc Nephrol 2001;12:684A.
68. Bandyopadhyay A, Lopez Casillas F, Malik SN, Montiel JL, Mendoza V, Yang J, Sun L-Z. Antitumor activity of recombinant soluble betaglycan in human breast cancer xenograft. Cancer Research 2002;62:4690-4695.